Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review

被引：0

作者：

Konings, Laura A. M. ^{[1
,2
]}

Miguelanez-Matute, Lorena ^{[1
]}

Boeren, Anna M. P. ^{[1
]}

van de Luitgaarden, Inge A. T. ^{[3
]}

Dirksmeier, Femme ^{[4
]}

de Knegt, Rob J. ^{[5
]}

Tushuizen, Maarten E. ^{[6
]}

Grobbee, Diederick E. ^{[3
]}

Holleboom, Adriaan G. ^{[7
]}

Cabezas, Manuel Castro ^{[1
,2
,3
]}

机构：

[1] Franciscus Gasthuis & Vlietland, Dept Internal Med, Rotterdam, Netherlands

[2] Erasmus MC, Dept Internal Med & Endocrinol, Rotterdam, Netherlands

[3] Julius Clin, Zeist, Netherlands

[4] Franciscus Gasthuis & Vlietland, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[5] Erasmus MC, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[6] LUMC, Dept Gastroenterol & Hepatol, Leiden, Netherlands

[7] Amsterdam UMC, Dept Internal Med, Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION | 2025年 / 55卷 / 04期

关键词：

MASH; MASLD; NAFLD; NASH; pharmacotherapy; T2DM; NONALCOHOLIC STEATOHEPATITIS; INSULIN SENSITIVITY; PIOGLITAZONE; LIRAGLUTIDE; SITAGLIPTIN; PREVALENCE; EXENATIDE; PLACEBO; TRIAL;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is closely related to type 2 diabetes mellitus (T2DM) through a common root in insulin resistance. The more severe stage, metabolic dysfunction-associated steatohepatitis (MASH), increases the risk for cardiovascular complications, liver cirrhosis and hepatocellular carcinoma. Several trials investigating established antidiabetic-drugs in patients with T2DM and MASLD have yielded promising results. Therefore, we aimed to systematically review the effect of T2DM-drug treatment on MALSD parameters.MethodsMedical databases were searched until January 2025 for controlled trials in patients with T2DM and MASLD/MASH. Studies that evaluated the effect of T2DM-medication on the severity of MASLD/MASH in T2DM patients were included. The quality of the studies was assessed by three independent reviewers using a set of Cochrane risk-of-bias tools.ResultsOf 1748 references, 117 studies fulfilled the inclusion-criteria and were assessed for eligibility in full-text. Fifty-two articles were included. Data included a total of 64.708 patients and study populations ranged from 9 to 50.742. Heterogeneity in study-design and analysis hampered the comparability of the results. Most evidence was present for GLP-1 receptor agonists, SGLT2-inhibitors and PPAR-gamma-agonists for regression of liver fibrosis and MASH.ConclusionStudies on the value of T2DM-drug treatment in the improvement of MASLD vary significantly in study design, size and quality. GLP-1 receptor agonists, PPAR-gamma-agonists, SGLT2-inhibitors may all be preferred pharmacological interventions for patients with MASLD/MASH and T2DM. Newer agents like dual GLP-1/GIP or triple GLP-1/GIP/Glucagon agonists will likely play an important role in the treatment of MASLD/MASH in the near future.

引用

页数：28